Department

Biochemistry

Preferred Sample Type

Luteinising Hormone (LH)

Suitable Specimen Types

  • Serum
  • EDTA Plasma
  • Li Hep Plasma
5 mL blood (250 µL serum/plasma min. vol.)

Sample Processing in Laboratory

Usual

Sample Preparation

Centrifuge

Turnaround Time

1 day

Sample Stability

4 ºC

Luteinising Hormone (LH)

General Information

LH is often used in conjunction with other tests (FSH, testosterone, oestradiol and progesterone) in the investigation of infertility in both men and women. LH levels are also useful in the investigation of menstrual irregularities (irregular periods) and to aid in the diagnosis of pituitary gland disorders. In children, FSH and LH are used to diagnose delayed and precocious (early) puberty.

In women, FSH and LH levels can help to tell the difference between primary ovarian failure (failure of the ovaries themselves) and secondary ovarian failure (failure of the ovaries due to disorders of either the pituitary gland or the hypothalamus in the brain). Increased levels of FSH and LH are consistent with primary ovarian failure. Causes of primary ovarian failure include developmental defects (Ovarian agenesis, Turner's syndrome, 17-alpha hydroxylase deficiency), radiation therapy (e.g. chemotherapy) or chronic anovulation due to factors such as Polycystic ovary syndrome (PCOS), adrenal disease, thyroid disease or an ovarian tumour.

When a woman enters the menopause and her ovaries stop working, FSH levels will rise.

Low levels of FSH and LH are consistent with secondary ovarian failure due to a pituitary or hypothalamic problem.

In men, LH controls the production of testosterone from the testes and FSH controls the production of sperm. High LH and FSH levels are due to primary testicular failure. This can be due to developmental defects in testicular growth or to testicular injury (e.g. viral infection, trauma, germ cell tumour, radiation therapy and autoimmune diseases).

Low levels of FSH and LH are consistent with pituitary or hypothalamic disorders.

In young children, high levels of FSH and LH and development of secondary sexual characteristics at an unusually young age are an indication of precocious (early) puberty. This is much more common in girls than in boys.

 

Patient Preparation

None

Notes

None Given

Reference Range

Males: 0.57 - 12.07 IU/L

Females

Follicular phase: 1.80 - 11.78 IU/L
Luteal phase: 0.56 - 14.0 IU/L
Mid Cycle: 7.59 - 89.08 IU/L
Post menopausal: 5.16 - 61.99 IU/L

Specifications

  • EQA Scheme?: Yes
  • EQA Status:

    NEQAS and WEQAS

Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018

HTA licence number is 12366

Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.

The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.

For further information contact Louise Fallon, Quality Manager, 0121 424 1235

UKAS HEFT